TN2013000411A1 - Branched 3-phenylpropionic acid derivatives and the use thereof - Google Patents

Branched 3-phenylpropionic acid derivatives and the use thereof

Info

Publication number: TN2013000411A1
Authority: TN; Tunisia
Prior art keywords: branched; acid derivatives; phenylpropionic acid; treating; preventing
Prior art date: 2011-04-13

Application number

TNP2013000411A

Other languages

English (en)

Inventor

Thomas Lampe

Michael Hahn

Johannes-Peter Stasch

Karl-Heinz Schlemmer

Frank Wunder

Volkhart Min-Jian Li

Eva-Maria Becker-Pelster

Friedericke Stoll

Andreas Knorr

Elisabeth Woltering

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-13

Filing date

2013-10-10

Publication date

2015-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45928886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000411(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-10-10 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2015-03-30 Publication of TN2013000411A1 publication Critical patent/TN2013000411A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Hematology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TNP2013000411A 2011-04-13 2013-10-10 Branched 3-phenylpropionic acid derivatives and the use thereof TN2013000411A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102011007272A DE102011007272A1 (de)	2011-04-13	2011-04-13	Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
PCT/EP2012/055474 WO2012139888A1 (fr)	2011-04-13	2012-03-28	Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation

Publications (1)

Publication Number	Publication Date
TN2013000411A1 true TN2013000411A1 (en)	2015-03-30

Family

ID=45928886

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000411A TN2013000411A1 (en)	2011-04-13	2013-10-10	Branched 3-phenylpropionic acid derivatives and the use thereof

Country Status (43)

Country	Link
US (6)	US8796335B2 (fr)
EP (1)	EP2697191B1 (fr)
JP (1)	JP5911950B2 (fr)
KR (1)	KR101944559B1 (fr)
CN (1)	CN103796989B (fr)
AP (1)	AP3482A (fr)
AR (1)	AR085586A1 (fr)
AU (1)	AU2012242122B2 (fr)
BR (1)	BR112013026466B1 (fr)
CA (1)	CA2832970C (fr)
CL (1)	CL2013002902A1 (fr)
CO (1)	CO6801742A2 (fr)
CR (1)	CR20130524A (fr)
CU (1)	CU24183B1 (fr)
CY (1)	CY1117183T1 (fr)
DE (1)	DE102011007272A1 (fr)
DK (1)	DK2697191T3 (fr)
DO (1)	DOP2013000239A (fr)
EA (1)	EA023990B1 (fr)
EC (1)	ECSP13012966A (fr)
ES (1)	ES2561753T3 (fr)
GT (1)	GT201300243A (fr)
HR (1)	HRP20160100T1 (fr)
HU (1)	HUE026859T2 (fr)
IL (1)	IL228677A (fr)
JO (1)	JO3091B1 (fr)
MA (1)	MA35039B1 (fr)
ME (1)	ME02310B (fr)
MX (1)	MX337712B (fr)
MY (1)	MY173877A (fr)
PE (1)	PE20140630A1 (fr)
PH (1)	PH12013502126A1 (fr)
PL (1)	PL2697191T3 (fr)
PT (1)	PT2697191E (fr)
RS (1)	RS54527B1 (fr)
SG (2)	SG193941A1 (fr)
SI (1)	SI2697191T1 (fr)
TN (1)	TN2013000411A1 (fr)
TW (1)	TWI549933B (fr)
UA (1)	UA110054C2 (fr)
UY (1)	UY33970A (fr)
WO (1)	WO2012139888A1 (fr)
ZA (1)	ZA201308490B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0775033B2 (ja)	1991-12-13	1995-08-09	松下電器産業株式会社	暗証番号照合方法及びその装置
DE102009012314A1 (de) *	2009-03-09	2010-09-16	Bayer Schering Pharma Aktiengesellschaft	Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
DE102009046115A1 (de)	2009-10-28	2011-09-08	Bayer Schering Pharma Aktiengesellschaft	Substituierte 3-Phenylpropansäuren und ihre Verwendung
JP5989660B2 (ja)	2010-12-07	2016-09-07	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	置換１−ベンジルシクロアルキルカルボン酸およびその使用
DE102011007272A1 (de) *	2011-04-13	2012-10-18	Bayer Pharma Aktiengesellschaft	Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
CN105503867B (zh)	2011-11-25	2019-01-11	阿德弗里奥药品有限责任公司	用于制备取代的5-氟-1h-吡唑并吡啶类化合物的方法
DE102012208530A1 (de)	2012-05-22	2013-11-28	Bayer Pharma AG	Substituierte Piperidinoacetamide und ihre Verwendung
WO2014084312A1 (fr) *	2012-11-30	2014-06-05	アステラス製薬株式会社	Composé imidazopyridine
WO2014186704A2 (fr) *	2013-05-17	2014-11-20	N30 Pharmaceuticals, Inc.	Nouveaux composés permettant le traitement de la fibrose kystique
WO2015011086A1 (fr)	2013-07-25	2015-01-29	Bayer Pharma Aktiengesellschaft	Stimulateurs de sgc ou activateurs de sgc et inhibiteurs de pde5 en combinaison avec un autre traitement pour la thérapie de la fibrose kystique
TW201625586A (zh)	2014-07-02	2016-07-16	諾華公司	環己烯－１－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625601A (zh)	2014-07-02	2016-07-16	諾華公司	噻吩－２－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625584A (zh)	2014-07-02	2016-07-16	諾華公司	茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TN2017000256A1 (en)	2014-12-18	2018-10-19	Bayer Pharma AG	Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
AU2016258847A1 (en)	2015-05-06	2017-11-16	Bayer Pharma Aktiengesellschaft	The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of Digital Ulcers (DU) concomitant to Systemic Sclerosis (SSc)
WO2017013010A1 (fr) *	2015-07-23	2017-01-26	Bayer Pharma Aktiengesellschaft	Stimulateurs et/ou activateurs de la guanylate-cyclase soluble (sgc) en association avec un inhibiteur de l'endopeptidase neutre (inhibiteur nep) et/ou des antagonistes d'une angiotensine ii et leur utilisation
EP3525778A1 (fr)	2016-10-11	2019-08-21	Bayer Pharma Aktiengesellschaft	Combinaison contenant des activateurs gcs et des antagonistes du récepteur des minéralocorticoïdes
EP3525779B1 (fr)	2016-10-11	2024-06-05	Bayer Pharma Aktiengesellschaft	Combinaison contenant le stimulateur sgc vericugat et l'antagoniste des récepteurs minéralcorticoïdes finerenone
WO2018153899A1 (fr)	2017-02-22	2018-08-30	Bayer Pharma Aktiengesellschaft	Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des stimulateurs et/ou activateurs de la guanylate cyclase soluble (sgc)
WO2019081353A1 (fr)	2017-10-24	2019-05-02	Bayer Aktiengesellschaft	Imidazopyridinamides substituées et leur utilisation
WO2019081456A1 (fr)	2017-10-24	2019-05-02	Bayer Aktiengesellschaft	Utilisation d'activateurs et de stimulateurs de sgc comprenant une sous-unité bêta2
SG11202004577VA (en)	2017-12-01	2020-06-29	Bayer Pharma AG	Method for producing (3s)-3-(4-chlor-3-{[(2s,3r)-2-(4-chlorphenyl)-4,4,4-trifluor-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient
EP3498298A1 (fr)	2017-12-15	2019-06-19	Bayer AG	Utilisation de stimulateurs sgc et d'activateurs sgc seuls ou en combinaison avec des inhibiteurs pde5 pour le traitement de troubles osseux, y compris l'ostéogénèse imparfaite (oi)
WO2019211081A1 (fr) *	2018-04-30	2019-11-07	Bayer Aktiengesellschaft	Utilisation d'activateurs de la gcs et de stimulateurs de la gcs pour le traitement de déficiences cognitives
JOP20200287A1 (ar)	2018-05-15	2020-11-09	Bayer Ag	بنزاميدات مستبدلة بـ 3،1- ثيازول-2- يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية
US11508483B2 (en)	2018-05-30	2022-11-22	Adverio Pharma Gmbh	Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
US20210283046A1 (en) *	2018-07-24	2021-09-16	Bayer Aktiengesellschaft	Pharmaceutical dosage form which can be administered orally and has modified release
JP2021532113A (ja)	2018-07-24	2021-11-25	バイエル・アクチエンゲゼルシヤフト	経口投与可能であり、放出を修飾した薬学的投薬形態
US10905667B2 (en)	2018-07-24	2021-02-02	Bayer Pharma Aktiengesellschaft	Orally administrable modified-release pharmaceutical dosage form
WO2020148379A1 (fr)	2019-01-17	2020-07-23	Bayer Aktiengesellschaft	Procédés permettant de déterminer si un sujet est apte à être traité avec un agoniste de guanylyle cyclase soluble (sgc)
WO2020164008A1 (fr)	2019-02-13	2020-08-20	Bayer Aktiengesellschaft	Procédé de préparation de microparticules poreuses
WO2020216669A1 (fr)	2019-04-23	2020-10-29	Bayer Aktiengesellschaft	Imidazopyridinamides substitués par un phényle et leur utilisation
BR112021021188A2 (pt)	2019-05-07	2021-12-14	Bayer Ag	Compostos inibidores de masp e usos dos mesmos
WO2020245342A1 (fr)	2019-06-07	2020-12-10	Bayer Aktiengesellschaft	Utilisation d'activateurs de sgc pour le traitement de maladies ophtalmologiques
EP3822265A1 (fr)	2019-11-15	2021-05-19	Bayer AG	Hydantoïnamides substitués comme antagonistes d'adamts7
EP3822268A1 (fr)	2019-11-15	2021-05-19	Bayer Aktiengesellschaft	Hydantoinamides substitués comme antagonistes d'adamts7
EP4011874A1 (fr)	2020-12-10	2022-06-15	Bayer Aktiengesellschaft	Acides carboxyliques de pyrazolo pipéridine substitués
EP4011873A1 (fr)	2020-12-10	2022-06-15	Bayer Aktiengesellschaft	Acides carboxyliques de pyrazolo pipéridine substitués
WO2022122914A1 (fr)	2020-12-10	2022-06-16	Bayer Aktiengesellschaft	Acides pyrazolo pipéridine carboxyliques substitués
CN116829545A (zh)	2020-12-10	2023-09-29	拜耳公司	取代的吡唑基哌啶羧酸
KR20230118143A (ko)	2020-12-10	2023-08-10	바이엘 악티엔게젤샤프트	안과 질환의 치료를 위한 sGC 활성화제의 용도
EP4339184A4 (fr) *	2021-05-14	2025-05-28	Medshine Discovery Inc.	Composés d'acide alkylcarboxylique et leur application
WO2023275796A1 (fr) *	2021-07-01	2023-01-05	Novartis Ag	Dérivés hétérocycliques utiles comme inhibiteurs de sphingosine-1-phosphate 3
WO2023284860A1 (fr) *	2021-07-15	2023-01-19	江苏恒瑞医药股份有限公司	Composé d'acide 3-phénylpropionique, son procédé de préparation et son application médicale
WO2023155873A1 (fr) *	2022-02-18	2023-08-24	江苏恒瑞医药股份有限公司	Composé d'acide carboxylique, son procédé de préparation et son utilisation dans le domaine pharmaceutique
JP2025518350A (ja)	2022-06-09	2025-06-12	バイエル・アクチエンゲゼルシヤフト	女性における駆出率が維持された心不全の治療に使用するための可溶性グアニル酸シクラーゼアクチベーター
CN120152950A (zh) *	2022-11-08	2025-06-13	康臣药业(内蒙古)有限责任公司	一种烷基羧酸类化合物的晶型及其应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en)	1974-11-18	1977-07-06	Alza Corp	Process for forming outlet passageways in pills using a laser
US4063064A (en)	1976-02-23	1977-12-13	Coherent Radiation	Apparatus for tracking moving workpiece by a laser beam
US4111202A (en)	1976-11-22	1978-09-05	Alza Corporation	Osmotic system for the controlled and delivery of agent over time
US4327725A (en)	1980-11-25	1982-05-04	Alza Corporation	Osmotic device with hydrogel driving member
US4765989A (en)	1983-05-11	1988-08-23	Alza Corporation	Osmotic device for administering certain drugs
NZ206600A (en)	1983-05-11	1987-01-23	Alza Corp	Osmotic drug delivery device
EP0277092B1 (fr)	1987-01-14	1992-01-29	Ciba-Geigy Ag	Système thérapeutique pour médicaments peu solubles
US5041453A (en)	1990-05-30	1991-08-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4
AU675689B2 (en)	1992-12-01	1997-02-13	Merck & Co., Inc.	Fibrinogen receptor antagonists
DE4301900A1 (de)	1993-01-25	1994-07-28	Bayer Ag	2-Oxochinolin-1-yl-methylphenylessigsäurederivate
US5643957A (en)	1993-04-22	1997-07-01	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
DE4326344A1 (de)	1993-08-05	1995-02-09	Thomae Gmbh Dr K	Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2722145B1 (fr)	1994-07-05	1996-09-27	Michelin & Cie	Bande de roulement pour pneumatique hivernaux
NL9401707A (nl)	1994-10-17	1996-06-03	Dsm Nv	Werkwijze voor de bereiding van 3-fenylpropaanzuur.
DE4443892A1 (de)	1994-12-09	1996-06-13	Bayer Ag	4-(Chinolin-2-yl-methoxy)-phenyl-essigsäurederivate
US5650386A (en)	1995-03-31	1997-07-22	Emisphere Technologies, Inc.	Compositions for oral delivery of active agents
DE19546918A1 (de)	1995-12-15	1997-06-19	Bayer Ag	Bicyclische Heterocyclen
EP0802192A1 (fr)	1996-04-17	1997-10-22	Bayer Ag	Phénylglycinamides d'acides hétérocycliques substitués ayant une activité antiathéroschlérotique et procédé pour leur préparation
DE19747261A1 (de)	1997-10-25	1999-04-29	Bayer Ag	Osmotisches Arzneimittelfreisetzungssystem
DE19821483A1 (de)	1998-05-14	1999-11-18	Hoechst Marion Roussel De Gmbh	Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834047A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Substituierte Pyrazolderivate
DE19834044A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Neue substituierte Pyrazolderivate
YU59801A (sh)	1999-02-24	2005-07-19	F. Hoffmann-La Roche Ag.	Fenil- i piridinil-derivati
KR100693771B1 (ko)	1999-04-28	2007-03-12	사노피-아벤티스 도이칠란트 게엠베하	Ｐｐａｒ 수용체 리간드로서의 트리아릴 산 유도체 및 이를 포함하는 약제학적 조성물
CN1331862C (zh)	1999-04-28	2007-08-15	萨诺费－阿文蒂斯德国有限公司	作为ppar受体配体的二芳基酸衍生物
DE19929065A1 (de)	1999-06-25	2000-12-28	Bayer Ag	Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
DE19943636A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AU7446600A (en)	1999-10-01	2001-05-10	Japan Energy Corporation	Novel diarylamide derivatives and use thereof as medicines
TWI262185B (en)	1999-10-01	2006-09-21	Eisai Co Ltd	Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
ATE407919T1 (de)	2000-05-29	2008-09-15	Kyorin Seiyaku Kk	Substituierte phenylpropionsäure-derivate
AU2001278771A1 (en)	2000-08-22	2002-03-04	Ono Pharmaceutical Co. Ltd.	Carboxylic acid derivatives, process for producing the same and drugs containingthe same as the active ingredient
AU2001288067A1 (en)	2000-09-21	2002-04-02	Sankyo Company Limited	Phenylpropionic acid derivatives
MXPA03003829A (es)	2000-11-04	2003-07-28	Aventis Pharma Ltd	Acidos alcanoicos substituidos.
AR031176A1 (es)	2000-11-22	2003-09-10	Bayer Ag	Nuevos derivados de pirazolpiridina sustituidos con piridina
CA2430846A1 (fr)	2000-12-05	2002-06-13	Kyorin Pharmaceutical Co., Ltd.	Derives de l'acide carboxylique substitues
DE60139025D1 (de)	2000-12-28	2009-07-30	Takeda Pharmaceutical	Alkansäurederivate, verfahren zu deren herstellung und deren verwendung
WO2002076959A1 (fr)	2001-03-23	2002-10-03	Takeda Chemical Industries, Ltd.	Derive heterocyclique a cinq membres d'acide alcanoique
JP4549021B2 (ja)	2001-03-30	2010-09-22	エーザイ・アール・アンド・ディー・マネジメント株式会社	ベンゼン化合物およびその塩
US20030105097A1 (en)	2001-05-14	2003-06-05	Pfizer Inc.	Alkylamide compounds
MXPA04001253A (es)	2001-08-09	2004-06-03	Ono Pharmaceutical Co	Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
WO2003016265A1 (fr)	2001-08-17	2003-02-27	Eisai Co., Ltd.	Compose cyclique et agoniste du recepteur ppar
US20030161882A1 (en)	2002-02-01	2003-08-28	Waterman Kenneth C.	Osmotic delivery system
DE10220570A1 (de)	2002-05-08	2003-11-20	Bayer Ag	Carbamat-substituierte Pyrazolopyridine
WO2004024705A1 (fr)	2002-09-10	2004-03-25	Takeda Pharmaceutical Company Limited	Composes heterocycliques a cinq elements
US20050234066A1 (en)	2004-04-15	2005-10-20	Agouron Pharmaceuticals, Inc.	Alpha substituted carboxylic acids
US20050187266A1 (en)	2003-04-15	2005-08-25	Pfizer Inc	Alpha substituted carboxylic acids
CN1812978A (zh)	2003-04-30	2006-08-02	药物研发有限责任公司	作为蛋白酪氨酸磷酸酶－1b抑制剂的苯基取代羧酸
US7816367B2 (en)	2004-02-27	2010-10-19	Amgen Inc.	Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
EP1786821B1 (fr)	2004-07-19	2009-09-16	Intercasting Corporation	Systeme et procede de reseautage dynamique a base de connaissances
EP1801698A1 (fr)	2004-08-10	2007-06-27	Microelectronica Española, S.A.	Unite de traitement et procede de gestion de memoire dans des systemes de traitement a ressources limitees
MY145712A (en) *	2004-09-15	2012-03-30	Janssen Pharmaceutica Nv	4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JP2008518926A (ja)	2004-10-28	2008-06-05	ジインスティチューツフォーファーマシューティカルディスカバリー、エルエルシー	置換フェニルアルカン酸
AU2005307818A1 (en)	2004-11-18	2006-05-26	The Institutes For Pharmaceutical Discovery, Llc	Heterocyclylbiphenyl derivates as protein Tyrosine phosphatase inhibitors
GT200500375A (es)	2004-12-20	2006-11-28		Derivados de piperidina y su uso como agentes antiinflamatorios
DE102004062475A1 (de)	2004-12-24	2006-07-06	Bayer Healthcare Ag	Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
PL372356A1 (pl)	2005-01-20	2006-07-24	ADAMED Sp.z o.o.	Nowe związki, pochodne kwasu 3-fenylopropionowego
CA2621164A1 (fr)	2005-08-26	2007-03-01	Shionogi & Co., Ltd.	Derive ayant une activite agoniste vis-a-vis du ppar
DE102005050377A1 (de)	2005-10-21	2007-04-26	Bayer Healthcare Ag	Heterocyclische Verbindungen und ihre Verwendung
CN101116660A (zh) *	2006-08-04	2008-02-06	瑟维尔实验室	抗动脉粥样化血栓形成的化合物在获得用于治疗血管疾病的药物中的用途
WO2009067493A2 (fr)	2007-11-19	2009-05-28	Envivo Pharmaceuticals, Inc.	Benzènes 1,3,5-trisubstitués pour le traitement de la maladie d'alzheimer et d'autres troubles
DE102008018675A1 (de)	2008-04-14	2009-10-15	Bayer Schering Pharma Aktiengesellschaft	Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung
PE20110136A1 (es)	2008-06-27	2011-03-17	Novartis Ag	Compuestos organicos
EP2179992A1 (fr)	2008-10-21	2010-04-28	Bayer Schering Pharma Aktiengesellschaft	Dérivés d'anilino-pyrimidine substitués par sulfone en tant qu'inhibiteurs de CDK, leur fabrication et leur utilisation en tant que médicaments
EP2179993A1 (fr)	2008-10-21	2010-04-28	Bayer Schering Pharma Aktiengesellschaft	Dérivés d'anilino-pyrimidine substitués par sulfoxide en tant qu'inhibiteurs de CDK, leur fabrication et leur utilisation en tant que médicaments
DE102008059206A1 (de)	2008-11-27	2010-06-10	Bayer Schering Pharma Aktiengesellschaft	Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
DE102009012314A1 (de)	2009-03-09	2010-09-16	Bayer Schering Pharma Aktiengesellschaft	Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
DE102009046115A1 (de) *	2009-10-28	2011-09-08	Bayer Schering Pharma Aktiengesellschaft	Substituierte 3-Phenylpropansäuren und ihre Verwendung
DE102010021637A1 (de)	2010-05-26	2011-12-01	Bayer Schering Pharma Aktiengesellschaft	Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2708539A1 (fr)	2010-07-09	2014-03-19	Bayer Intellectual Property GmbH	Pyrimidine et triazine condensés et leur utilisation
DE102010040233A1 (de)	2010-09-03	2012-03-08	Bayer Schering Pharma Aktiengesellschaft	Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de)	2010-11-04	2012-05-10	Bayer Schering Pharma Aktiengesellschaft	Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
JP5989660B2 (ja) *	2010-12-07	2016-09-07	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	置換１−ベンジルシクロアルキルカルボン酸およびその使用
DE102011007272A1 (de)	2011-04-13	2012-10-18	Bayer Pharma Aktiengesellschaft	Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
DE102012208530A1 (de)	2012-05-22	2013-11-28	Bayer Pharma AG	Substituierte Piperidinoacetamide und ihre Verwendung
PL2875003T3 (pl)	2012-07-20	2017-05-31	Bayer Pharma Aktiengesellschaft	Nowe kwasy 5-aminotetrahydrochinolino-2-karboksylowe i ich zastosowanie
EP3525778A1 (fr)	2016-10-11	2019-08-21	Bayer Pharma Aktiengesellschaft	Combinaison contenant des activateurs gcs et des antagonistes du récepteur des minéralocorticoïdes
SG11202004577VA (en)	2017-12-01	2020-06-29	Bayer Pharma AG	Method for producing (3s)-3-(4-chlor-3-{[(2s,3r)-2-(4-chlorphenyl)-4,4,4-trifluor-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient
US20200237648A1 (en)	2018-07-24	2020-07-30	Bayer Pharma Aktiengesellschaft	Orally administrable modified-released pharmaceutical dosage form
US10905667B2 (en)	2018-07-24	2021-02-02	Bayer Pharma Aktiengesellschaft	Orally administrable modified-release pharmaceutical dosage form
US20210283046A1 (en)	2018-07-24	2021-09-16	Bayer Aktiengesellschaft	Pharmaceutical dosage form which can be administered orally and has modified release
WO2020245342A1 (fr)	2019-06-07	2020-12-10	Bayer Aktiengesellschaft	Utilisation d'activateurs de sgc pour le traitement de maladies ophtalmologiques

2011
- 2011-04-13 DE DE102011007272A patent/DE102011007272A1/de not_active Withdrawn
2012
- 2012-03-26 TW TW101110304A patent/TWI549933B/zh not_active IP Right Cessation
- 2012-03-26 UY UY0001033970A patent/UY33970A/es active IP Right Grant
- 2012-03-27 JO JOP/2012/0066A patent/JO3091B1/ar active
- 2012-03-27 US US13/431,934 patent/US8796335B2/en active Active
- 2012-03-27 AR ARP120101024A patent/AR085586A1/es active IP Right Grant
- 2012-03-28 UA UAA201313123A patent/UA110054C2/ru unknown
- 2012-03-28 ES ES12711861.0T patent/ES2561753T3/es active Active
- 2012-03-28 PL PL12711861T patent/PL2697191T3/pl unknown
- 2012-03-28 SG SG2013071758A patent/SG193941A1/en unknown
- 2012-03-28 SG SG10201602852WA patent/SG10201602852WA/en unknown
- 2012-03-28 EP EP12711861.0A patent/EP2697191B1/fr active Active
- 2012-03-28 PH PH1/2013/502126A patent/PH12013502126A1/en unknown
- 2012-03-28 JP JP2014504240A patent/JP5911950B2/ja active Active
- 2012-03-28 KR KR1020137029773A patent/KR101944559B1/ko not_active Expired - Fee Related
- 2012-03-28 EA EA201301154A patent/EA023990B1/ru not_active IP Right Cessation
- 2012-03-28 MX MX2013011774A patent/MX337712B/es active IP Right Grant
- 2012-03-28 MA MA36326A patent/MA35039B1/fr unknown
- 2012-03-28 HR HRP20160100TT patent/HRP20160100T1/hr unknown
- 2012-03-28 PT PT127118610T patent/PT2697191E/pt unknown
- 2012-03-28 PE PE2013002244A patent/PE20140630A1/es active IP Right Grant
- 2012-03-28 AU AU2012242122A patent/AU2012242122B2/en not_active Ceased
- 2012-03-28 CA CA2832970A patent/CA2832970C/fr active Active
- 2012-03-28 DK DK12711861.0T patent/DK2697191T3/en active
- 2012-03-28 WO PCT/EP2012/055474 patent/WO2012139888A1/fr not_active Ceased
- 2012-03-28 ME MEP-2016-12A patent/ME02310B/me unknown
- 2012-03-28 RS RS20160043A patent/RS54527B1/sr unknown
- 2012-03-28 HU HUE12711861A patent/HUE026859T2/en unknown
- 2012-03-28 CU CUP2013000137A patent/CU24183B1/es active IP Right Grant
- 2012-03-28 AP AP2013007164A patent/AP3482A/xx active
- 2012-03-28 BR BR112013026466-7A patent/BR112013026466B1/pt not_active IP Right Cessation
- 2012-03-28 CN CN201280028866.2A patent/CN103796989B/zh active Active
- 2012-03-28 SI SI201230442T patent/SI2697191T1/sl unknown
- 2012-03-28 MY MYPI2013701912A patent/MY173877A/en unknown
2013
- 2013-10-02 IL IL228677A patent/IL228677A/en active IP Right Grant
- 2013-10-10 CR CR20130524A patent/CR20130524A/es unknown
- 2013-10-10 EC EC2013012966A patent/ECSP13012966A/es unknown
- 2013-10-10 CO CO13241304A patent/CO6801742A2/es active IP Right Grant
- 2013-10-10 CL CL2013002902A patent/CL2013002902A1/es unknown
- 2013-10-10 TN TNP2013000411A patent/TN2013000411A1/fr unknown
- 2013-10-11 GT GT201300243A patent/GT201300243A/es unknown
- 2013-10-11 DO DO2013000239A patent/DOP2013000239A/es unknown
- 2013-11-12 ZA ZA2013/08490A patent/ZA201308490B/en unknown
2014
- 2014-06-13 US US14/304,171 patent/US20140309307A1/en not_active Abandoned
2016
- 2016-01-26 CY CY20161100069T patent/CY1117183T1/el unknown
- 2016-05-18 US US15/158,331 patent/US10023528B2/en active Active
2018
- 2018-06-06 US US16/001,146 patent/US10259776B2/en active Active
- 2018-12-21 US US16/230,957 patent/US20190185415A1/en not_active Abandoned
2020
- 2020-06-18 US US16/904,786 patent/US11377417B2/en active Active

Also Published As

Publication number	Publication date
IL228677A0 (en)	2013-12-31
CR20130524A (es)	2014-01-31
CN103796989A (zh)	2014-05-14
TWI549933B (zh)	2016-09-21
AU2012242122B2 (en)	2017-06-01
CO6801742A2 (es)	2013-11-29
EP2697191A1 (fr)	2014-02-19
AP2013007164A0 (en)	2013-10-31
CN103796989B (zh)	2017-03-01
CA2832970C (fr)	2019-06-04
US20200385335A1 (en)	2020-12-10
PH12013502126A1 (en)	2014-01-13
US20180282262A1 (en)	2018-10-04
US20130079412A1 (en)	2013-03-28
US8796335B2 (en)	2014-08-05
SI2697191T1 (sl)	2016-03-31
AR085586A1 (es)	2013-10-09
EA023990B1 (ru)	2016-08-31
SG193941A1 (en)	2013-11-29
ZA201308490B (en)	2015-08-26
CY1117183T1 (el)	2017-04-05
HRP20160100T1 (hr)	2016-02-26
EP2697191B1 (fr)	2015-11-18
PL2697191T3 (pl)	2016-04-29
PE20140630A1 (es)	2014-05-24
CA2832970A1 (fr)	2012-10-18
CU24183B1 (es)	2016-07-29
US10023528B2 (en)	2018-07-17
JP2014522383A (ja)	2014-09-04
ES2561753T3 (es)	2016-02-29
GT201300243A (es)	2015-02-23
JO3091B1 (ar)	2017-03-15
US20160264515A1 (en)	2016-09-15
JP5911950B2 (ja)	2016-04-27
IL228677A (en)	2017-06-29
US20140309307A1 (en)	2014-10-16
MX2013011774A (es)	2013-11-01
BR112013026466A2 (pt)	2020-09-01
WO2012139888A1 (fr)	2012-10-18
KR101944559B1 (ko)	2019-01-31
US11377417B2 (en)	2022-07-05
UY33970A (es)	2012-11-30
DK2697191T3 (en)	2016-02-15
MY173877A (en)	2020-02-26
PT2697191E (pt)	2016-03-11
BR112013026466B1 (pt)	2022-05-10
ME02310B (me)	2016-06-20
CL2013002902A1 (es)	2014-02-14
ECSP13012966A (es)	2013-11-29
US20190185415A1 (en)	2019-06-20
HUE026859T2 (en)	2016-07-28
RS54527B1 (sr)	2016-06-30
SG10201602852WA (en)	2016-05-30
US10259776B2 (en)	2019-04-16
TW201302674A (zh)	2013-01-16
DOP2013000239A (es)	2014-01-15
AU2012242122A1 (en)	2013-10-24
NZ616274A (en)	2016-02-26
AP3482A (en)	2015-12-31
UA110054C2 (uk)	2015-11-10
DE102011007272A1 (de)	2012-10-18
CU20130137A7 (es)	2014-01-29
KR20140021008A (ko)	2014-02-19
MX337712B (es)	2016-03-15
MA35039B1 (fr)	2014-04-03
EA201301154A1 (ru)	2014-04-30

Publication	Publication Date	Title
TN2013000411A1 (en)	2015-03-30	Branched 3-phenylpropionic acid derivatives and the use thereof
PH12015501494A1 (en)	2015-09-07	Method for producing substituted 5-fluoro-1h-pyrazolopyrimidines
PH12014502496A1 (en)	2015-01-12	Bicyclically substituted uracils and the use thereof
PH12013501143A1 (en)	2013-07-08	Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
MX362689B (es)	2019-02-01	Procedimiento de preparacion de derivados de acido 3,5-bis(fluoroalquil)pirazol-4-carboxilico y 3,5-bis(fluoroalquil) pirazoles.
SG10201705091YA (en)	2017-07-28	METHOD FOR PRODUCING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID DERIVATIVE, AND METHOD FOR PURIFYING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID
PL2797863T5 (pl)	2019-06-28	Sposób wytwarzania 1,3-butadienu
MX2013013436A (es)	2013-12-06	Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
WO2011009532A3 (fr)	2011-04-21	Dérivés 17-hydroxy-17-pentafluoroéthyl-estra-4,9(10)-diène-11-benzylidène, procédés de préparation et utilisation pour le traitement de maladies
MX2012010317A (es)	2012-12-17	ß-HIDROXIALQUILAMIDAS, METODO PARA SU PRODUCCION Y SU USO.
MX2011012233A (es)	2012-04-19	Soluciones de retinoide topicas.
MX361998B (es)	2018-10-16	Procedimiento de preparacion de derivados de acido 4-haloalquil-3-mercapto-2 sustituido-hidroxibenzoico.
WO2014009204A8 (fr)	2015-03-12	Oxasilacycles et leur procédé de production
GB2523674A (en)	2015-09-02	Compounds as inhibitor of DNA double-strand break repair, methods and applications thereof
MX343856B (es)	2016-11-25	Procedimiento para la preparación de derivados 1-h-pirrolidin-2,4-diona.
TN2015000095A1 (en)	2016-06-29	Macrolide derivatives, preparation thereof and therapeutic use thereof
PH12015500262A1 (en)	2015-03-30	Novel pyridine derivatives
EP2886548A4 (fr)	2016-01-20	Procédé de fabrication d'un dérivé d'acide borinique, et nouveau dérivé d'acide boronique
PH12014501760A1 (en)	2014-11-10	Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro[5.5]undecanes
MX2013010001A (es)	2013-12-06	Derivados de androstanediol como compuestos reguladores del crecimiento de las plantas.
HRP20180032T8 (hr)	2018-12-14	Postupak dobivanja spoja 4,4,7-trifluor-1,2,3,4-tetrahidro-5h-1-benzazepina i međuprodukta u njegovoj sintezi
MX2013002990A (es)	2013-11-26	Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
TN2013000243A1 (en)	2014-11-10	Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
TN2014000227A1 (en)	2015-09-30	Method for producing substituted 5-fluoro-1h-pyrazolopyridines
TN2013000128A1 (en)	2014-06-25	Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation